...
首页> 外文期刊>Cancer epidemiology >Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma
【24h】

Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma

机译:SOX6表达降低使肝细胞癌预后不良

获取原文
获取原文并翻译 | 示例
           

摘要

Background and aim: SOX6, a member of the D subfamily of sex determining region y-related transcription factors, plays critical roles in cell fate determination, differentiation and proliferation. It has been identified as a tumor suppressor or an oncogene in different human cancers. However, the role of SOX6 in the development and progression of hepatocellular carcinoma (HCC) has not been explored. The aim of this study was to investigate the expression of SOX6 in HCC and determine its correlation with tumor progression and prognosis. Methods: 130 HCC patients who had undergone curative liver resection were selected and immunohistochemistry, Western blotting, and quantitative real time polymerase chain reaction (Q-PCR) were performed to analyze SOX6 expression in the respective tumors. Results: Q-PCR, immunohistochemistry and Western blotting consistently confirmed the decreased expression of SOX6 at both mRNA and protein levels in HCC tissues compared with their adjacent nonneoplastic tissues (P< 0.01). Additionally, the expression of SOX6, determined by immunohistochemistry, was negatively correlated with the tumor stage (P= 0.003) and serum AFP (P= 0.02). Moreover, HCC patients with lower SOX6 expression had worse 5-year disease-free survival and 5-year overall survival than those with high SOX6 expression (P= 0.006 and 0.001, respectively). Furthermore, the Cox proportional hazards model showed that the decreased expression of SOX6 was an independent poor prognostic factor for both 5-year disease-free survival (hazards ratio [HR] = 2.398, 95% confidence interval [CI] = 1.601-5.993, P= 0.01) and 5-year overall survival (HR = 3.569, CI = 1.381-7.290, P= 0.008) in HCC. Conclusion: These findings provide evidence for the first time that SOX6 expression was decreased in HCC, which correlated with poor prognosis, suggesting that SOX6 may be a novel and potential prognostic marker for HCC.
机译:背景与目的:SOX6是与性别相关的区域y相关转录因子D子家族的成员,在细胞命运的确定,分化和增殖中起着至关重要的作用。在不同的人类癌症中已将其鉴定为肿瘤抑制因子或致癌基因。但是,尚未探讨SOX6在肝细胞癌(HCC)的发生和发展中的作用。这项研究的目的是调查肝癌中SOX6的表达并确定其与肿瘤进展和预后的关系。方法:选择130例行根治性肝切除术的HCC患者,并进行免疫组织化学,Western印迹和定量实时聚合酶链反应(Q-PCR)分析各肿瘤中SOX6的表达。结果:Q-PCR,免疫组织化学和Western印迹一致证实与邻近的非肿瘤组织相比,肝癌组织中SOX6在mRNA和蛋白水平上的表达均降低(P <0.01)。此外,通过免疫组织化学测定的SOX6表达与肿瘤分期(P = 0.003)和血清AFP(P = 0.02)呈负相关。此外,与SOX6高表达的患者相比,SOX6低表达的HCC患者的5年无病生存期和5年总生存期较差(分别为P = 0.006和0.001)。此外,Cox比例风险模型显示SOX6表达降低是5年无病生存的独立不良预后因素(风险比[HR] = 2.398,95%置信区间[CI] = 1.601-5.993, P = 0.01)和HCC的5年总生存率(HR = 3.569,CI = 1.381-7.290,P = 0.008)。结论:这些发现首次为肝癌中SOX6表达的降低提供了证据,这与预后不良有关,表明SOX6可能是肝癌的一种新型且潜在的预后标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号